Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission-confounded by the gut microbiome?

Leong RWL, Kaakoush NO, Yau YY, Wasinger VC.

Aliment Pharmacol Ther. 2019 Apr;49(8):1086-1087. doi: 10.1111/apt.15171. No abstract available.

PMID:
30920041
2.

Molecular Pathophysiology of Epithelial Barrier Dysfunction in Inflammatory Bowel Diseases.

Lee JY, Wasinger VC, Yau YY, Chuang E, Yajnik V, Leong RW.

Proteomes. 2018 Mar 31;6(2). pii: E17. doi: 10.3390/proteomes6020017. Review.

3.

Serological Epithelial Component Proteins Identify Intestinal Complications in Crohn's Disease.

Yau YY, Leong RWL, Pudipeddi A, Redmond D, Wasinger VC.

Mol Cell Proteomics. 2017 Jul;16(7):1244-1257. doi: 10.1074/mcp.M116.066506. Epub 2017 May 10.

4.

Reverse-polynomial dilution calibration methodology extends lower limit of quantification and reduces relative residual error in targeted peptide measurements in blood plasma.

Yau YY, Duo X, Leong RW, Wasinger VC.

Mol Cell Proteomics. 2015 Feb;14(2):441-54. doi: 10.1074/mcp.M114.040790. Epub 2014 Dec 9.

5.

Bimodal plasma metabolomics strategy identifies novel inflammatory metabolites in inflammatory bowel diseases.

Yau YY, Leong RW, Shin S, Bustamante S, Pickford R, Hejazi L, Campbell B, Wasinger VC.

Discov Med. 2014 Sep;18(98):113-24.

Supplemental Content

Loading ...
Support Center